Systemic Inflammatory Response Post Alemtuzumab and Low-Dose Total Body Irradiation in Pediatric Patients with Sickle Cell Disease: A Case SeriesRozalyn Chok1, Katherine Girgulis2, Robert S Nickel3,4, Gregory MT Guilcher2*.Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Lucile Packard Children’s Hospital, Stanford University, Stanford, California, United States.Section of Oncology/BMT, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada.Division of Hematology and Division of Blood and Marrow Transplantation, Children’s National Hospital, Washington, District of Columbia, United States.Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States.*Correspondence to:Gregory Guilcher, MD, Section of Oncology/BMT, University of Calgary, Alberta Children’s Hospital, 28 Oki Drive Trail NW, Calgary, AB, T3B 6A8. Email: [email protected] word count: 786 wordsRunning title: SIRS Post TBI in SCD PatientsKeywords: Sickle Cell Disease, Total Body Irradiation, Alemtuzumab, Hematopoietic Stem Cell TransplantFigures: 0Tables: 2